Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

Rhea-AI Summary

Terns Pharmaceuticals (Nasdaq: TERN) announced its participation in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 12:50 PM ET. The event will address serious diseases, including NASH and obesity, which are central to Terns' clinical focus. A live webcast will be accessible on Terns' investor relations page, with a replay available for 30 days post-presentation. The company is advancing a pipeline featuring small-molecule therapies and combination treatments aimed at improving patient outcomes.

FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity, today announced that management will be participating in a NASH discussion panel at the Cowen 42^nd Annual Healthcare Conference on Tuesday, March 8 at 12:50pm ET.

A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

 

FAQ

When is Terns Pharmaceuticals participating in the Cowen 42nd Annual Healthcare Conference?

Terns Pharmaceuticals will participate in the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 12:50 PM ET.

How can I watch the live webcast of Terns Pharmaceuticals' conference participation?

The live webcast of Terns Pharmaceuticals' participation will be available on their investor relations page.

What diseases are Terns Pharmaceuticals focusing on?

Terns Pharmaceuticals focuses on developing therapies for serious diseases such as NASH and obesity.

What is included in Terns Pharmaceuticals' development pipeline?

Terns' pipeline includes clinical stage programs like an FXR agonist, a VAP-1 inhibitor, and a THR-β agonist.

How long will the replay of the Terns Pharmaceuticals webcast be available?

The replay of the Terns Pharmaceuticals webcast will be available for 30 days following the presentation.